History

1857

Caspar Friedrich Hausmann founds a pharmacy in St Gallen, Switzerland pioneering iron products.

1927

Sixteen pharmacists establish a joint purchasing centre in Western Switzerland, forming the basis of the future Galenica Ltd.

1944

Pharmacist René Grosclaude founds Vifor Ltd. producing non-prescription medicines.

1952

Ferrum Hausmann, intravenous iron product, developed by Laboratorien Hausmann AG is first introduced in Switzerland. This brand later develops into Venofer®.

1964

Iron (III) polymaltose complex, the future Maltofer®, is introduced in the market.

1977

Galenica acquires Vifor Ltd., taking on their first manufacturing capability.

1983

Galenica acquires Laboratorien Hausmann AG.

1991

Vifor (International) Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products.

1997

Vifor Ltd. invests in new product development for its over-the-counter drugs to support international growth.

2000

FDA (US Food and Drug Administration) approves intravenous iron treatment for the treatment of haemodialysisdependent CKD patients in the US market.

2007

Ferinject® receives regulatory approval in Switzerland and 18 EU countries.

2008

Foundation of Vifor Pharma through the acquisition of Aspreva Pharmaceutical Corporation and integration of Vifor Ltd. and Vifor (International) Ltd.

2009

Acquisition of OM Pharma, a specialist Swiss biotechnology and pharmaceutical company.

2010/2011

Galenica, (55%) and Fresenius Medical Care (45%) form Vifor Fresenius Medical Care Renal Pharma, a new company operating in nephrology.

2013

Injectafer® (US brand name of Ferinject®) receives US FDA approval for Iron Deficiency Anaemia treatment.

2013

Velphoro® receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis.

2014

Velphoro® receives EU marketing authorisation.

2014

Galenica lays foundation for Vifor Pharma to become a stand-alone global specialty pharma company.

2015

Velphoro® receives Swissmedic approval.

2015

Veltassa® receives US FDA approval for the treatment of hyperkalemia.

2016

Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE®.

2016

Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets.

2016

ESC guidelines recommend Ferinject®.

2016

Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market.

2016

The US biopharmaceutical company Relypsa was acquired by Galenica and integrated into Vifor Pharma, further strengthening Vifor Pharma’s product Portfolio.

2016

Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases.